Stemgent develops technology and application solutions to advance stem cell research, working alongside leading stem cell scientists. The company focuses on simplifying and supporting cellular reprogramming research by producing products designed by leading researchers worldwide. It maintains scientific development sites in Cambridge, Massachusetts and San Diego, California. According to the article, Stemgent has about 40-plus employees and is roughly four-and-a-half years old. The firm has taken $11.3M in equity in its largest round to date and has filed for more than $40M in debt and equity investment to date per SEC filings.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2012